A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours

被引：0
|
作者：
Christophe Le Tourneau
Jean-Pierre Delord
Nuria Kotecki
Edith Borcoman
Carlos Gomez-Roca
Ségolène Hescot
Christiane Jungels
Anne Vincent-Salomon
Vincent Cockenpot
Lauriane Eberst
Audrey Molé
Wael Jdey
Françoise Bono
Véronique Trochon-Joseph
Hélène Toussaint
Christelle Zandanel
Olga Adamiec
Olivier de Beaumont
Philippe Alexandre Cassier
机构：
[1] Institut Curie,Department of Drug Development and Innovation (D3i)
[2] IUCT-Oncopole,Institut Claudius Régaud
[3] Institut Jules Bordet,Medical Oncology Clinic
[4] Institut Curie,Department of Tumor Biology
[5] Centre Léon Bérard,Medical Oncology
[6] Onxeo,Clinical Department
[7] Onxeo,Scientific Department
来源：
British Journal of Cancer | 2020年 / 123卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1481 / 1489
页数：8
相关论文
共 50 条
  • [31] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    Papadopoulos, K. P.
    Markman, B.
    Tabernero, J.
    Patnaik, A.
    Heath, E. I.
    DeCillis, A.
    Laird, D.
    Aggarwal, S. K.
    Nguyen, L.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours
    Scheulen, M.
    Mross, K.
    Richly, H.
    Nokay, B.
    Frost, A.
    Scharr, D.
    Lee, K. H.
    Saunders, O.
    Hilbert, J.
    Fietz, O.
    EJC SUPPLEMENTS, 2010, 8 (07): : 158 - 159
  • [33] A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors
    Tsimberidou, Apostolia
    Vandross, Andrae L.
    Sommerhalder, David
    Joseph, Charmaine
    Chandhasin, Chandtip
    Perabo, Frank
    Clarke, Michael F.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [34] A PHASE 1A/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Abbas, A.
    Strauss, J.
    Janku, F.
    Karim, R.
    Olszanski, A.
    Luke, J. J.
    Leach, K.
    Iyer, R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A7 - A8
  • [35] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
    Doi, T.
    Murakami, H.
    Wan, K.
    Miki, M.
    Kotani, H.
    Sakamoto, N.
    Yamamoto, N.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    I M E Desar
    J N H Timmer-Bonte
    D M Burger
    W T A van der Graaf
    C M L van Herpen
    British Journal of Cancer, 2010, 103 : 1637 - 1643
  • [37] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    Desar, I. M. E.
    Timmer-Bonte, J. N. H.
    Burger, D. M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1637 - 1643
  • [38] Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study
    Mamot, Christoph
    Ritschard, Reto
    Wicki, Andreas
    Stehle, Gregor
    Dieterle, Thomas
    Bubendorf, Lukas
    Hilker, Christoph
    Deuster, Stefanie
    Herrmann, Richard
    Rochlitz, Christoph
    LANCET ONCOLOGY, 2012, 13 (12): : 1234 - 1241
  • [39] A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.
    Shi, Yehui
    Bai, Guiying
    Wang, Peng
    Cai, Dongpo
    Chen, Yue
    Wang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study
    Ito, Yoshinori
    Suenaga, Mitsukuni
    Hatake, Kiyohiko
    Takahashi, Shunji
    Yokoyama, Masahiro
    Onozawa, Yusuke
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Hashigami, Kiyoshi
    Hasegawa, Hirotaka
    Takenaka, Nobuko
    Boku, Narikazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (04) : 278 - 286
12345